ReviewTheranostics2019
Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.
Review in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Biomimetic Targeted Drug Delivery for Liver Failure in Abdominal Sepsis: Focus on Autologous Erythrocyte Ghosts.International journal of molecular sciences · 2026Review
- Beyond autologousMolecular therapy. Oncology · 2026Review
- Nanomaterials and exercise interventions: A synergistic approach for atherosclerosis therapy (Review).International journal of molecular medicine · 2026Review
- A Chemically InducedVaccines · 2026Article
- Theragenerative Nanomaterials: Integrating Therapy, Regeneration, and Diagnosis-Navigating the Shared Pathways Between Tissue Repair and Malignancy.International journal of nanomedicine · 2026Review
- Green Synthesis of Zinc Oxide Nanoparticles and Their Application in Anticancer Drug Delivery - A Review.International journal of nanomedicine · 2026Review
- Exploring the Potential of Zein Nanoparticles in Personalised Cancer Therapy, Highlighting Their Various Methodologies, Applications and Challenges.Journal of cellular and molecular medicine · 2025Review
- Red blood cells-derived components as biomimetic functional materials: Matching versatile delivery strategies based on structure and function.Bioactive materials · 2025Review
- The Role of Inorganic Nanomaterials in Overcoming Challenges in Colorectal Cancer Diagnosis and Therapy.Pharmaceutics · 2025Review
- Development, Characterization, and Evaluation of Chi-Tn mAb-Functionalized DOTAP-PLGA Hybrid Nanoparticles Loaded with Docetaxel for Lung Cancer Therapy.Pharmaceutics · 2025Article
- Sonodynamic and magnetic targeting platelet-membrane biomimetic platform for glioblastoma therapy.Frontiers in bioengineering and biotechnology · 2025Article
- Nano Delivery System for Atherosclerosis.Journal of functional biomaterials · 2024Review
- Review
- Comparative analysis of Escherichia coli Nissle 1917 ghosts quality: a study of two chemical methods.Archives of microbiology · 2024Article
- Revolutionizing Cancer Treatment: The Promising Horizon of Zein Nanosystems.ACS biomaterials science & engineering · 2024Review
- Erythrocytes Nanoparticle Delivery: A Boon for Targeting Tumor.Advanced pharmaceutical bulletin · 2024Review
- Research progress of cell membrane biomimetic nanoparticles for circulating tumor cells.Frontiers in oncology · 2024Review
- Fe-HCOF-PEGInternational journal of nanomedicine · 2024Article
- Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective.Drug delivery · 2023Review
- Cell primitive-based biomimetic nanomaterials for Alzheimer's disease targeting and therapy.Materials today. Bio · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a daunting and cureless disease, which is responsible for one-sixth of human deaths worldwide. These mortality rates have been expected to rise in the future due to the side effects of conventional treatments (chemotherapy, radiotherapy, and surgery), which can be addressed by applying nanomedicine. In order to escape from biological barriers, such nanomedicine should be mimicked and designed to be stealthy while navigating in the bloodstream. To achieve this, scientists take advantage of erythrocytes (red blood cells; RBCs) as drug carriers and develop RBC membrane (RBCm) coating nanotechnology. Thanks to the significant advances in nanoengineering, various facile surface functionalization methods can be applied to arm RBCm with not only targeting moieties, but also imaging agents, therapeutic agents, and nanoparticles, which are useful for theranostic nanomedicine. This review focuses on refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.